Operator: Good day, everyone. Welcome to the Freeline Therapeutics Business Update Conference Call. At this time, all participants are in listen-only mode.
In an effort to improve its cash runway, the UK biotech company Freeline Therapeutics has paused the development of a gene therapy candidate for the rare metabolic condition Fabry disease. Instead, the company will refocus its efforts on a gene therapy for a different metabolic condition called Gaucher disease.
Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics Agreement grants Freeline rights to develop and commercialise AAV gene therapies using